The Use of Toulmin's Argumentation Model in Solving The Drug Conflict Problems

The field of argumentation in Artificial Intelligence (AI) has witnessed a great increase an important cognitive to deal with uncertain information and conflicting opinions. This has led to a number of interesting lines of research in this field and related fields, giving rise to computational models of the argument as a promising research field. The remedies conflict problem is considered one of the challenges in the field of medicine the world. This paper makes use of Toulmin's argumentation model to deal with conflicting problems within the medicine field. In addition, inference rules were used for associating a patient's symptoms and patient history(premises) with remedies use, eventually leading to medications diagnosis for patient (claims). After that, several remedy features are used to compete for the support and the attack (pros and cons) for each remedy item. A decision is made during the qualifier phase in Toulmin's model about whether or not the drug should be used based on the highest value of support or attack. The dataset consists of 200 patients as samples for two heart diseases (hypertension, angina pectoris). It is collected from the Iraqi educational hospitals, annotated by a team of experts working in the medical field. The performance achieved in the proposed model in hypertension and angina pectoris diseases were 78% and 83%, respectively, using the confusion matrix method.

[1]  Ahmed T. Sadiq,et al.  A Survey of Toulmin Argumentation Approach for Medical Applications , 2022, International Journal of Online and Biomedical Engineering (iJOE).

[2]  Tiago Oliveira,et al.  Resolving Conflicts in Clinical Guidelines using Argumentation , 2019, AAMAS.

[3]  Rafael H. Bordini,et al.  Argumentation-Based Reasoning in BDI Agents Using Toulmin's Model , 2018, 2018 7th Brazilian Conference on Intelligent Systems (BRACIS).

[4]  Carlos José Pereira de Lucena,et al.  Practical Reasoning in an Argumentation-based Decision BDI Agent: a Case Study for Participatory Management of Protected Areas , 2017, SEKE.

[5]  Szymon Wilk,et al.  Comprehensive mitigation framework for concurrent application of multiple clinical practice guidelines , 2017, J. Biomed. Informatics.

[6]  Rafael H. Bordini,et al.  Knowledge Representation for Argumentation in Agent-Oriented Programming Languages , 2016, 2016 5th Brazilian Conference on Intelligent Systems (BRACIS).

[7]  F. J. U. Rivera,et al.  Physician-patient argumentation and communication, comparing Toulmin's model, pragma-dialectics, and American sociolinguistics. , 2015, Cadernos de saude publica.

[8]  C. Tannenbaum,et al.  Understanding and preventing drug–drug and drug–gene interactions , 2014, Expert review of clinical pharmacology.

[9]  Trevor J. M. Bench-Capon,et al.  Practical reasoning as presumptive argumentation using action based alternating transition systems , 2007, Artif. Intell..

[10]  Guillermo Ricardo Simari,et al.  Defeasible Argumentation Support for an Extended BDI Architecture , 2007, ArgMAS.

[11]  Andrea Omicini,et al.  Co-argumentation Artifact for Agent Societies , 2007, ArgMAS.

[12]  H. Anders,et al.  [Chronic renal failure]. , 2006, MMW Fortschritte der Medizin.

[13]  David Hitchcock,et al.  Good Reasoning on the Toulmin Model , 2005, Arguing on the Toulmin Model.

[14]  Antonis C. Kakas,et al.  Argumentation based decision making for autonomous agents , 2003, AAMAS '03.

[15]  Claudette Cayrol,et al.  A Reasoning Model Based on the Production of Acceptable Arguments , 2002, Annals of Mathematics and Artificial Intelligence.

[16]  Vasa Curcin,et al.  Towards an Argumentation System for Supporting Patients in Self-Managing Their Chronic Conditions , 2018, MedRACER+WOMoCoE@KR.

[17]  Karin Baier,et al.  The Uses Of Argument , 2016 .

[18]  Rafael H. Bordini,et al.  An Approach for Argumentation-based Reasoning Using Defeasible Logic in Multi-Agent Programming Languages , 2014 .

[19]  Tudor Berariu,et al.  An Argumentation Framework for BDI Agents , 2013, IDC.